Select a link below to review the latest annoucements from Ocucure Therapeutics. All links are in PDF format, which requires Adobe Reader.

 

• 2010 — XIX biennial meeting of the International Society for Eye Research Conference Poster, Montreal, Canada.

   

  - ISER 2010 - Session Planner. 2010 — Association of Research in Vision and Ophthalmology Conference Poster:

   

  - OC-10X, A Tubulin Inhibitor, Inhibits Neovasclarization in a Non-human Primate Model of AMD.
  



• October 2009 — OcuCure Therapeutics will present for the 2009 Mid Atlantic Bio Conference. (Requires Adobe Reader)
  
  
• August 2009 — Roanoke Times Article. Local companies on the verge of taking a significant step into the health care industry. (Requires Adobe Reader)
  
  
• July 8, 2009 — OcuCure Therapeutics Ophthalmic Lead Compound for AMD Demonstrates Robust Efficacy in Primates. (Requires Adobe Reader)
  
  
• June 17, 2009 — OcuCure Therapeutics: Topical Vascular Targeting Agent Demonstrates Long Term Safety. (Requires Adobe Reader)


• 2009 — Association of Research in Vision and Ophthalmology Conference Asia Poster:

   

  - Evaluation of Retinal Function Using Full-Field Electroretinography during Cataractogenesis in the Galactosemic Rat Model. (Requires Adobe Reader)



• 2008 — Association of Research in Vision and Ophthalmology (ARVO) Conference Posters:

   

  - Effects of OC-10X, a Novel Inhibitor of Tubulin, in a Rat Choroidal Neovascularizton Model.

   

  - OC-10X, a Non-Toxic Inhibitor of Tubulin, Inhibits Vascular Endothelial Cell Proliferation Both in vitro and in vivo.

   

  - OC-10X, a Non-Toxic Inhibitor of Tubulin, Inhibits Vascular Endothelial Cell Proliferation Both in vitro and in vivo.



• January 6, 2006 — Carilion Biomedical Institute Invests in OcuCure Therapeutics. (Requires Adobe Reader)
  
  
• November 8, 2006 — OcuCure Therapeutics: Developing Novel Eye Drop Treatments for Wet and Dry Age-related Macular Degeneration. (Requires Adobe Reader)